By Stephen Nakrosis

Vanda Pharmaceuticals said the Food and Drug Administration accepted the filing of the company's new drug application for tradipitant to treat symptoms of gastroparesis.

Gastroparesis is characterized by delayed gastric emptying with symptoms including bloating, nausea, vomiting and abdominal pain, the company said Monday.

Vanda said about 6 million patients in the U.S. have gastroparesis, many of whom remain undiagnosed.

Write to Stephen Nakrosis at stephen.nakrosis@wsj.com

(END) Dow Jones Newswires

December 04, 2023 18:30 ET (23:30 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.
Grafico Azioni Vanda Pharmaceuticals (NASDAQ:VNDA)
Storico
Da Apr 2024 a Mag 2024 Clicca qui per i Grafici di Vanda Pharmaceuticals
Grafico Azioni Vanda Pharmaceuticals (NASDAQ:VNDA)
Storico
Da Mag 2023 a Mag 2024 Clicca qui per i Grafici di Vanda Pharmaceuticals